Nightingale Health Oyj Class B (DE:7XE)
FRANKFURT:7XE
Germany Market
Holding DE:7XE?
Track your performance easily

Nightingale Health Oyj Class B (7XE) Income Statement

1 Followers

Nightingale Health Oyj Class B Income Statement

Last quarter (Q2 2023), Nightingale Health Oyj Class B's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, Nightingale Health Oyj Class B's net income was €―. See Nightingale Health Oyj Class B’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19
Total Revenue
-€ 2.31M€ 2.08M€ 1.78M€ 2.06M
Cost of Revenue
-€ 1.04M€ 318.96K€ 13.61K€ 436.97K
Gross Profit
-€ 1.28M€ 1.76M€ 1.77M€ 1.63M
Operating Expense
-€ 14.89M€ 7.04M€ 5.11M€ 5.41M
Operating Income
-€ -13.61M€ -5.28M€ -3.34M€ -3.78M
Net Non Operating Interest Income Expense
-€ -792.00K€ -5.91M€ -382.52K€ -238.18K
Other Income Expense
-----
Pretax Income
-€ -16.19M€ -11.19M€ -3.73M€ -4.02M
Tax Provision
-€ -103.00K€ 2.10K€ 2.78K€ -917.72
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-€ -16.09M€ -11.19M€ -3.73M€ -4.02M
Basic EPS
-----
Diluted EPS
-----
Basic Average Shares
-----
Diluted Average Shares
-----
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-€ 15.92M€ 7.36M€ 5.12M€ 5.85M
Net Income From Continuing And Discontinued Operation
-€ -16.09M€ -11.19M€ -3.73M€ -4.02M
Normalized Income
-€ -14.04M€ -11.19M€ -3.73M€ -4.02M
Interest Expense
-€ 767.00K€ 8.17M€ 382.71K€ 241.17K
EBIT
-€ -15.43M€ -3.02M€ -3.35M€ -3.78M
EBITDA
-€ -11.18M€ -2.55M€ -3.12M€ -3.55M
Currency in EUR

Nightingale Health Oyj Class B Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis